Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Piper Sandler initiates Abbott Laboratories with “overweight” rating, $131 PT

admin by admin
September 19, 2024
in Stock
0
Piper Sandler initiates Abbott Laboratories with “overweight” rating, $131 PT
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Investing.com — Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an “overweight” rating and a price target of $131 per share. 

Piper Sandler emphasizes Abbott’s attractive valuation, strong financial outlook, and key business strengths that position it well in the large-cap medtech sector.

Central to Piper Sandler’s recommendation is Abbott’s financial health and growth trajectory. Abbott’s revenues are projected to grow to $44.84 billion in 2025 from $41.68 billion in 2024, reflecting a 7.6% increase. 

This revenue growth is boosted by a return to double-digit earnings per share (EPS) growth in 2025, with adjusted EPS forecasted to rise to $5.14 in 2025 from $4.65 in 2024, a 10.5% rise. 

Abbott’s EPS is expected to climb to $5.74 in 2026, maintaining a strong growth rate of 11.7%. The company’s current price of $114.88, combined with its earnings prospects and valuation at 22.3x 2025 estimated EPS, provides what Piper Sandler describes as a compelling entry point for investors​.

The company’s medical technology segment, which accounts for approximately 44% of total revenue (excluding COVID-19 testing), is a particular standout. 

Piper Sandler projects this division to achieve double-digit growth from 2024 through 2026. Key products such as FreeStyle Libre, a continuous glucose monitoring (CGM) device, and MitraClip, used in structural heart therapy, are expected to remain strong growth drivers. 

Piper Sandler also flagged Abbott’s innovation pipeline, which is rich with new products and technological advancements. Among the most critical are the Lingo CGM, aimed at the wellness market, and the upcoming Volt pulsed field ablation (PFA) catheter, expected to launch in 2026. 

A critical element of Piper Sandler’s positive outlook on Abbott is the company’s ability to maintain double-digit EPS growth, particularly as it moves past the pandemic-driven fluctuations in COVID-19 testing revenues. 

The analysts project that Abbott will emerge from 2024 with stronger EPS growth, which they expect to continue into 2025 and 2026. The company’s solid performance across key sectors such as medical devices, diagnostics, pharmaceuticals, and nutrition is expected to drive this improvement​.

Abbott’s financial health, underscored by a strong balance sheet, further bolsters the bullish view. As of June 2024, Abbott held $7.0 billion in cash, with a manageable debt-to-EBITDA ratio of 0.64, which is favorable compared to its peers. 

Piper Sandler also noted Abbott’s consistent dividend payments, which provide additional stability for investors. Abbott has a history of paying dividends for 402 consecutive quarters, with its annual dividend yield standing at 2.0% in 2023. 

Despite this optimistic outlook, Piper Sandler acknowledges that certain risks remain. The ongoing litigation regarding Abbott’s Similac Special Care 24 formula and its alleged connection to necrotizing enterocolitis (NEC) is one such challenge. 

While this product represents a small portion of Abbott’s overall revenue (around $9 million in 2023), potential legal liabilities could have a material impact. 

However, Piper Sandler believes that the market has already priced in much of this risk and that the resolution of the litigation may not significantly impact the company’s long-term growth.

Competition is another area of focus, particularly in Abbott’s electrophysiology (EP) business. The emergence of pulse field ablation (PFA) technologies from competitors such as Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) could slow growth in this segment over the next few years. Although Abbott is developing its own PFA technology, it is expected to enter the market later than its rivals, which may cause the EP segment to lag until 2026. 

Another factor that could affect Abbott’s performance is foreign exchange (FX) exposure. Given that 61% of its revenue comes from international markets, fluctuations in currency exchange rates could present headwinds, especially as the global economic landscape remains volatile.

This post appeared first on investing.com

Previous Post

Exclusive-Shell faces delay in German refinery stake sale, sources say

Next Post

European stocks climb after hefty Fed cut; Next soars after outlook lift

admin

admin

Next Post
European stocks climb after hefty Fed cut; Next soars after outlook lift

European stocks climb after hefty Fed cut; Next soars after outlook lift

Trending News

Renault shares tumble after profit warning, leadership shake-up; analysts slash PTs

Renault shares tumble after profit warning, leadership shake-up; analysts slash PTs

July 16, 2025
Trump turns up heat on India with new tariff strike expected within next 24 hours

Trump turns up heat on India with new tariff strike expected within next 24 hours

August 5, 2025
Investor bullishness hits high, sparking ‘sell signal’ for global stocks: BofA survey

Investor bullishness hits high, sparking ‘sell signal’ for global stocks: BofA survey

October 15, 2024
Subscribe to Insightful Word


    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025
    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    August 28, 2025
    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    August 28, 2025

    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025

    Latest News

    • Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in
    • SentinelOne stock price forecast ahead of earnings: buy or sell?
    • Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.